Autonomic Phenotype Before and After Akt Inhibition
| Status: | Recruiting |
|---|---|
| Conditions: | Skin Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - 80 |
| Updated: | 2/7/2015 |
| Start Date: | May 2012 |
| End Date: | May 2016 |
| Contact: | Satish Raj, MD, MSCI |
| Email: | adcresearch@vanderbilt.edu |
| Phone: | 615-322-2931 |
Autonomic Phenotype Before and After Akt Inhibition: Akt Therapy for Melanoma Sub-study
Some Akt inhibitors have produced functional cardiovascular effects such as marked
hypotension that may limit their clinical benefit. There are no current data on whether
this autonomic failure presents in humans at clinically used doses. We will test the
hypothesis that Akt inhibition causes an acute decrease in sympathetic tone and lowers blood
pressure.
hypotension that may limit their clinical benefit. There are no current data on whether
this autonomic failure presents in humans at clinically used doses. We will test the
hypothesis that Akt inhibition causes an acute decrease in sympathetic tone and lowers blood
pressure.
Inclusion Criteria:
- Diagnosed with melanoma with a BRAF mutation and relapse following therapy with a
BRAF inhibitor
- Enrolled in a clinical trial through the Vanderbilt Ingram Cancer Center (VICC)
including an arm with an oral Akt inhibitor
- Able and willing to provide informed consent
Exclusion Criteria:
- Factors which in the investigator's opinion would prevent the participant from
completing the protocol, including poor compliance during previous studies or an
unpredictable schedule
- Unable to give informed consent
We found this trial at
1
site
Vanderbilt University Vanderbilt offers undergraduate programs in the liberal arts and sciences, engineering, music, education...
Click here to add this to my saved trials
